{"name": "Tolerx",
 "permalink": "tolerx",
 "crunchbase_url": "http://www.crunchbase.com/company/tolerx",
 "homepage_url": "http://www.tolerx.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@tolerx.com",
 "phone_number": "617-354-8100",
 "description": "",
 "created_at": "Thu Dec 02 07:10:31 UTC 2010",
 "updated_at": "Sat Dec 18 00:48:41 UTC 2010",
 "overview": "\u003Cp\u003ETolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company\u00e2\u20ac\u2122s products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[149,
       59],
      "assets/images/resized/0011/2557/112557v1-max-150x150.png"],
     [[149,
       59],
      "assets/images/resized/0011/2557/112557v1-max-250x250.png"],
     [[149,
       59],
      "assets/images/resized/0011/2557/112557v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Cofounder, President \u0026 CEO",
    "person":
     {"first_name": "Douglas",
      "last_name": "J. Ringler",
      "permalink": "douglas-j-ringler",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Thomas",
      "last_name": "A. Shea",
      "permalink": "thomas-a-shea",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$1.5M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=29\u0026aid=DJFVLS0020101201e6c10005l\u0026r=Rss\u0026s=DJFVLS",
    "source_description": "Tolerx Raises $1.5M R\u0026D Funding For Cancer Drug ",
    "raised_amount": 1500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 12,
    "funded_day": 1,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "300 Technology Square",
    "address2": "3rd Floor",
    "zip_code": "02139",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "has initiated a Phase 1 clinical trial of its TRX518, a therapy designed to enhance the immune system by enabling T cells to be more effective in attacking cancer cells",
    "stoned_year": 2010,
    "stoned_month": 12,
    "stoned_day": 14,
    "source_url": "http://www.masshightech.com/stories/2010/12/13/daily26-Tolerx-launches-Phase-1-trial-of-cancer-treatment.html",
    "source_text": null,
    "source_description": "Tolerx launches Phase 1 trial of cancer treatment",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Tolerx",
      "permalink": "tolerx"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}